Bowie Capital Management LLC Makes New $462,000 Investment in Alto Neuroscience, Inc. (NYSE:ANRO)

Bowie Capital Management LLC purchased a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 43,186 shares of the company’s stock, valued at approximately $462,000. Bowie Capital Management LLC owned 0.16% of Alto Neuroscience at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ANRO. Rhumbline Advisers bought a new position in Alto Neuroscience in the 2nd quarter valued at about $113,000. Bank of New York Mellon Corp acquired a new position in shares of Alto Neuroscience during the second quarter valued at approximately $252,000. University of Texas Texas AM Investment Managment Co. bought a new stake in Alto Neuroscience during the first quarter worth approximately $340,000. TD Asset Management Inc acquired a new stake in Alto Neuroscience in the second quarter worth approximately $928,000. Finally, Zimmer Partners LP bought a new position in Alto Neuroscience during the 1st quarter valued at $1,151,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Wednesday, June 12th. Wedbush initiated coverage on shares of Alto Neuroscience in a report on Tuesday, September 3rd. They set an “outperform” rating and a $29.00 target price for the company. Finally, Rodman & Renshaw initiated coverage on shares of Alto Neuroscience in a research report on Friday, June 21st. They issued a “buy” rating and a $43.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $33.80.

Insider Buying and Selling at Alto Neuroscience

In other news, insider Adam Savitz purchased 12,069 shares of the business’s stock in a transaction dated Tuesday, July 9th. The stock was bought at an average cost of $12.60 per share, with a total value of $152,069.40. Following the purchase, the insider now directly owns 36,920 shares of the company’s stock, valued at $465,192. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Alto Neuroscience Stock Up 3.5 %

Shares of ANRO opened at $13.17 on Friday. The company has a 50-day moving average of $11.99 and a two-hundred day moving average of $13.03. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04. Alto Neuroscience, Inc. has a one year low of $7.91 and a one year high of $24.00.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.07. As a group, equities analysts anticipate that Alto Neuroscience, Inc. will post -2.64 earnings per share for the current year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.